SVRA News and Press, Savara Inc.

2024-06-28 09:07:27 ET More on Savara Savara: Today's Data 'Win' Rouses Market All Too Briefly Savara: The Binary Bet On Phase 3 Data Savara surges after late-stage trial win for lead asset against rare lung disease Seeking Alpha’s Quant Rating on Sava...

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 26,246,720 shares of its common stock at a price of $3.81 per share before deducting underwriting discounts and commissions, fo...

2024-06-27 10:15:02 ET Guggenheim analyst issues BUY recommendation for SVRA on June 27, 2024 08:56AM ET. The previous analyst recommendation was Buy. SVRA was trading at $3.84 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...

2024-06-27 10:00:08 ET Vamil Divan from Guggenheim issued a price target of $10.00 for SVRA on 2024-06-27 08:56:00. The adjusted price target was set to $10.00. At the time of the announcement, SVRA was trading at $3.84. The overall price target consensus is at $10.50 wi...

2024-06-27 07:15:04 ET H.C. Wainwright analyst issues BUY recommendation for SVRA on June 27, 2024 06:03AM ET. The previous analyst recommendation was Buy. SVRA was trading at $3.84 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...

2024-06-27 07:00:03 ET Andrew Fein from H.C. Wainwright issued a price target of $10.00 for SVRA on 2024-06-27 06:03:00. The adjusted price target was set to $10.00. At the time of the announcement, SVRA was trading at $3.84. The overall price target consensus is at $11....

2024-06-26 15:13:41 ET Summary Savara Inc. is a biotech company focused on rare lung diseases that joined the Nasdaq in 2017. Today, management shared the news that lead candidate, molgramostim met primary and secondary endpoints in a Phase 3 study in patients with Autoimmune Pulm...

2024-06-26 12:30:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for SVRA on June 26, 2024 10:59AM ET. The previous analyst recommendation was Outperform. SVRA was trading at $3.61 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-06-26 07:00:39 ET More on Savara Savara: The Binary Bet On Phase 3 Data Seeking Alpha’s Quant Rating on Savara Historical earnings data for Savara Financial information for Savara Read the full article on Seeking Alpha For further ...

Statistically Significant Improvement in Percent Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) Versus Placebo at Week 24 (Primary Endpoint) and Week 48 (Secondary Endpoint) Statistically Significant Improvement in St. George’s Respiratory Questionnaire (S...